Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Acquires IP Related to miR-21 Modulation

Premium

Regulus Therapeutics this week announced that it has acquired from the University of Wuerzburg the exclusive rights to intellectual property covering methods for modulating microRNA-21.

According to the company, the miRNA has been shown to be dysregulated in mouse models of cardiac disease and fibrosis, and "antagonizing miR-21 with therapeutic oligonucleotides … inhibits fibrosis and attenuates cardiac function in such models."

Regulus, which is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, is currently developing an miR-21-targeting drug as an anti-fibrotic agent.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.